Navigation Links
Alexza's Staccato® Nicotine Licensed to Cypress Bioscience
Date:8/26/2010

MOUNTAIN VIEW, Calif., Aug. 26 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has licensed its Staccato nicotine technology to Cypress Bioscience, Inc. (Nasdaq: CYPB).  The Staccato nicotine technology is a novel electronic multidose delivery system designed to help people stop smoking.  The Staccato nicotine technology is intended to improve on a well-validated smoking cessation approach by delivering nicotine via inhalation, mimicking the nicotine effects of smoking without the harmful side effects associated with cigarettes.

"The Staccato system is a broad technology platform and Alexza has more Staccato-based product candidates than we can currently afford to develop on our own.  In early July, we outlined our strategy to advance Staccato-based product candidates into development through self-funding and through collaborations," said Thomas B. King, Alexza President and CEO.  "Today's announcement of the licensing of our Staccato nicotine technology to Cypress, along with our recently announced plans to advance AZ-007 (Staccato zaleplon) into Phase 2 clinical development, are examples of our execution of this dual-tracked development strategy."

Financial Information

According to the terms of the agreement, Cypress will pay Alexza an upfront payment of $5 million to acquire the worldwide license for the Staccato nicotine technology.  In addition, following the completion of certain preclinical and clinical milestones relating to the Staccato nicotine technology, Cypress will be obligated to pay to Alexza an additional technology transfer payment of $1 million.  Alexza will have a carried interest of 10% (subject to adjustment in certain circumstances) in the net proceeds of any sale or license by Cypress of
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Alexza Pharmaceuticals Updates Staccato® Pipeline and Outlines Pipeline Development Strategy
2. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
3. Care to Care Licensed to Manage High-cost Radiology in Virginia
4. Liquid Tissue(R) Patent Licensed for Amyloidosis Proteomic Assay
5. Stem Cell Sciences Announces the Creation of the Worlds First Authentic Rat Embryonic Stem Cells from its Exclusively Licensed Technology
6. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
9. SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
10. InQ Biosciences Appoints John Ryder as Senior Vice President, Sales & Marketing
11. Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... FREDERICK, Md. , May 23, 2013  BioElectronics ... safe consumer medical devices, comments on the FDA panel ... Public Advisory Panel Reclassification – Pulsed Shortwave Therapy Meeting ... Gaithersburg, MD , USA.  The focus of the ... instructed the panel to focus solely on the application ...
(Date:5/23/2013)... 2013 Halozyme Therapeutics, Inc. (NASDAQ: ... David A. Ramsay as ... Vice President, Corporate Development at Halozyme. ... his established financial management experience and his recent ... our commercial group for the last four years, ...
(Date:5/23/2013)... Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), ... present a company overview at the Deutsche Bank 38 th ... 2013 at 8:40 a.m. ET in Boston, MA. ... presentation will be available on the "Investors & Media" section ... will be available on the Isis Web site within 48 ...
Breaking Medicine Technology:BioElectronics and Pulsed Shortwave Therapy Make Progress 2Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference 2
... Advanced Life Sciences,Holdings, Inc. (Nasdaq: ADLS ... with the National Institute of Allergy and ... biodefense,research, under which the NIAID will conduct ... as a treatment for,anthrax and other high-priority ...
... Compound, AHLi-11, Slated for IND Filing By ... ... Quark Pharmaceuticals, Inc., a,clinical-stage biopharmaceutical company focused on discovering and,developing novel ... the State University of New York at,Buffalo, Center for Hearing & ...
Cached Medicine Technology:Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 2Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 3Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 4Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 2Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 3Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 4
(Date:5/23/2013)... New York, New York (PRWEB) May 23, 2013 ... dedicated to protecting the rights of victims injured by ... that Senior Litigation Counsel Matthew J. McCauley has been ... entitled In Re: Mirena IUD Products Liability Litigation (Case ... states that Co-Lead and Liaison Counsel are to submit ...
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 EnvirOasis, ... the contractor and ESCO market is pleased to announce ... Consortium (DLC) Listed LED products. EnvirOasis has been ... fixtures and retrofit kits and has recently brought ... LED (Light Emitting Diode) is energy efficient lighting ...
(Date:5/23/2013)... News) -- The sensation of itching is hardwired into ... a small molecule released in the spinal cord, according ... say this molecule, known as natriuretic polypeptide b (Nppb), ... system. Ultimately, this signal is experienced as an itch. ... similar, the researchers concluded that a similar process probably ...
(Date:5/23/2013)... May 23 (HealthDay News) -- Teen birth rates in the ... to a new government report. Overall, the rate of ... one half from 1991 to 2011 -- from about 62 ... 1,000. From 2007 to 2011, the most recent time ... 31. During that time, rates fell at least 30 ...
(Date:5/23/2013)... (HealthDay News) -- A shortage of a critical tuberculosis ... the United States to contain the spread of the ... drug, isoniazid (INH), was first used in 1951 and ... core of any first-line treatment for tuberculosis (TB). Patients ... according to the U.S. Centers for Disease Control and ...
Breaking Medicine News(10 mins):Health News:U.S. District Court Appoints Parker Waichman LLP’s Matthew J. McCauley to Leadership Role in Mirena IUD Litigation 2Health News:EnvirOasis Lighting Announces Energy Star and Design Lights Consortium LED Products 2Health News:Got an Itch? Mouse Study May Help Explain Why 2Health News:U.S. Teen Birth Rate Plummets: Report 2Health News:U.S. Teen Birth Rate Plummets: Report 3Health News:Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 2
... good job of aggressively treating the early stages of ... diagnosis. The study involved 467 hospitals spread across 12 ... that patients may be treated less aggressively when they ... able to confirm the diagnosis,” said Chadwick Miller, M.D., ...
... Heart failure patients with untreated sleep apnea are more likely to ... ,The study followed 164 patients with heart failure for ... apnea (OSA) had double the death rate of those patients who ... OSA, the death rate was 24% in contrast to 12% for ...
... in the fight against obesity has started delivering results in ... pilot program was started in one of the middle schools ... eating habits among school children. ,Today nearly ... this three year old program called ‘Healthy School.’ ...
... that smoking and binge drinking among teenage girls have ... the health risks seem less important than those of ... young people correctly see cigarettes and alcohol as a ... to reflect that, Ofsted opined. Pupils also felt let ...
... NHS services’, UK ‘s Health Minister Patricia Hewitt launched ... select their hospital and doctor, as well as access information on ... to put patients at the heart of the NHS and making ... a crucial part of that. “Patients will soon be able to ...
... welcomed the Government’s decision to officially recognise the Australian ... for rural GPs. ,“Rural GPs are the ... ,“Formal recognition for rural GPs who complete ... workforce in rural and regional areas.” ,The ...
Cached Medicine News:Health News:Doctors Treat Early Heart Attacks Before Labs Could Confirmation It 2Health News:Doctors Treat Early Heart Attacks Before Labs Could Confirmation It 3Health News:Sleep Disorder Linked to Heart Failure Patient Deaths 2Health News:Sleep Disorder Linked to Heart Failure Patient Deaths 3Health News:Campaign Against Obesity Taken to Schools in US 2Health News:Parents To Blame For Soaring Counts Of Binge-Drinkers And Smokers 2Health News:NHS Online- Promise Of ‘Choices’ To Patien 2